SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001753763-20-000001
Filing Date
2020-02-19
Accepted
2020-02-19 15:58:35
Documents
1
Period of Report
2020-02-13

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_doc.html 4  
1 PRIMARY DOCUMENT primary_doc.xml 4 5979
  Complete submission text file 0001753763-20-000001.txt   7459
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Issuer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 5251 DTC PARKWAY, SUITE 285 GREENWOOD VILLAGE CO 80111
Business Address
Scott John K Jr. (Reporting) CIK: 0001753763 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35076 | Film No.: 20629546